SCHEMBL2632301

SCHEMBL2632301

CC(=O)NCc1ccc(Cl)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
FAAH O00519 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 2/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51
KMT2A Q03164 2/20 0.50
RAB9A P51151 2/20 0.50
NAMPT P43490 2/20 0.50
CYP2C9 P11712 1/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.49
ATM Q13315 1/20 0.49
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC6 Q9UBN7 1/20 0.47
VHL P40337 1/20 0.46
BPTF Q12830 1/20 0.45
FPR2 P25090 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811285 1.00 ALDH1A1 (0.57) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL3704245 0.84 L3MBTL1 (0.56) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL5012151 0.83 FAAH (0.61) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL255686 0.83 KDM4E (0.56) ALDH1A1MAPTKDM4EKMT2ARAB9A
SCHEMBL763479 0.83 KDM4E (0.51) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL625919 0.83 CYP2C9 (0.61) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL27799938 0.82 NAMPT (0.53) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL19323949 0.82 ALDH1A1 (0.53) ALDH1A1FAAHL3MBTL1MAPTKDM4E
SCHEMBL24016013 0.81 KMT2A (0.51) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL3604595 0.81 KMT2A (0.51) ALDH1A1MAPTKDM4EKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020249821-A1 NOVEL ARGINASE INHIBITORS RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-12-17 WO disclosed
EP-2719688-B1 Process for producing tetrazolyloxime derivatives NIPPON SODA CO (JP) 2016-07-20 EP disclosed
WO-2016012333-A1 PESTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2016-01-28 WO disclosed
US-9212148-B2 Functionalizing reagents and their uses GLYTHERA LIMITED (GB) 2015-12-15 US disclosed
EP-2719686-B1 Process to halogenate a picoline derivative NIPPON SODA CO (JP) 2015-12-02 EP disclosed
EP-2373675-B1 THIOL-FUNCTIONALISING REAGENTS AND THEIR USES GLYTHERA LTD (GB) 2015-10-21 EP disclosed
EP-2719687-B1 Process to make a bromopicoline derivative NIPPON SODA CO (JP) 2015-09-16 EP disclosed
EP-2886132-A1 Thiol-functionalising reagents and their uses Glythera Limited (GB) 2015-06-24 EP disclosed
US-9018385-B2 Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative NIPPON SODA CO., LTD. (JP) 2015-04-28 US disclosed
US-9012653-B2 Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative NIPPON SODA CO., LTD. (JP) 2015-04-21 US disclosed
EP-2546236-A1 COMPOUND CONTAINING PYRIDINE RING AND METHOD FOR PRODUCING HALOGENATED PICOLINE DERIVATIVE AND TETRAZOLYLOXIME DERIVATIVE Nippon Soda Co., Ltd. (JP) 2013-01-16 EP disclosed
US-20130012713-A1 COMPOUND CONTAINING PYRIDINE RING AND METHOD FOR PRODUCING HALOGENATED PICOLINE DERIVATIVE AND TETRAZOLYLOXIME DERIVATIVE NIPPON SODA CO., LTD 2013-01-10 US disclosed
US-20120101254-A1 FUNCTIONALISING REAGENTS AND THEIR USES Iksuda Therapeutics Limited (GB) 2012-04-26 US disclosed
WO-2010070300-A2 FUNCTIONALISING REAGENTS AND THEIR USES THE UNIVERSITY OF BATH (GB) 2010-06-24 WO disclosed
EP-0722933-B1 Process for the preparation of chloromethylpyridine derivatives and acylaminomethyl pyridines as intermediates BAYER AG (DE) 2002-10-09 EP disclosed
EP-0691331-B1 Process for the preparation of n-acylated 2-chloro-5-aminomethyl-pyridines BAYER AG (DE) 2001-10-10 EP disclosed
US-5623076-A Process for the preparation of chloromethylpyridines BAYER AKTIENGESELLSCHAFT (DE) 1997-04-22 US disclosed
US-5580983-A Process for the preparation of N-acylated 2-chloro-5-aminomethylpyridines BAYER AKTIENGESELLSCHAFT (DE) 1996-12-03 US disclosed
EP-0722933-A1 Process for the preparation of chloromethylpyridine derivatives and acylaminomethyl pyridines as intermediates BAYER AG (DE) 1996-07-24 EP disclosed
EP-0691331-A1 Process for the preparation of n-acylated 2-chloro-5-aminomethyl-pyridines BAYER AG (DE) 1996-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101254-A1 FUNCTIONALISING REAGENTS AND THEIR USES VNN1, FGB, LNPEP ALDH1A1 2427/4885FAAH 1900/4885L3MBTL1 2965/4885
US-20130012713-A1 COMPOUND CONTAINING PYRIDINE RING AND METHOD FOR PRODUCING HALOGENATED PICOLINE DERIVATIVE AND TETRAZOLYLOXIME DERIVATIVE CBR3, PNPO, AADAC ALDH1A1 1365/4885FAAH 4209/4885L3MBTL1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.